AI Summary
✦ ClarthaAstraZeneca Pharma India is a biopharmaceutical company manufacturing and marketing medicines in India and internationally. Oncology brands TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex drive growth, alongside cardiovascular, renal, metabolic, immunological, respiratory, and rare-disease therapies. A new breast-cancer approval for ENHERTU expands its oncology opportunity, while quarterly revenue growth near 30% supports operating scale. However, Q1 profit fell 32% to ₹38 crore despite higher revenue, indicating near-term margin pressure. Revenue grew 32.6% year-on-year and profit increased 62%, but declining margins weaken earnings quality. ROE stands at 22.8%, although debt-to-equity of 12.68 indicates extreme leverage amplifies reported shareholder returns and financial risk. At 107.4 times earnings, the stock is overvalued and trades at a substantial premium to growth. Positive sentiment and oncology expansion support the outlook, but leverage, margin compression, and dependence on continued product approvals remain key open
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
Analyst coverage unavailable
Fundamentals
Fundamentals institutional score is 71 using EVA spread proxy 10.8%; growth durability 32.8.
Valuation
Valuation institutional score is 16 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
No usable analyst target or recommendation data was available.
Technical Structure
Technicals institutional score is 50 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 10 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. fundamentals provide support, while valuation and technical structure remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 6.9% above historical median. Valuation is rising — currently in the overvalued zone (z-score: +0.48). Confidence: 78%.
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
83.39
Current
116.93
Overvalued
125.40
Undervalued
90.95
5Y Average
56.59
Current
79.34
Overvalued
79.73
Undervalued
32.31
5Y Average
6.23
Current
8.73
Overvalued
8.77
Undervalued
3.55
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 43.7x Premium | +17% vs avg | +51.8% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.7x Premium | +17% vs avg | -25.8% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 38.6x Fair | +3% vs avg | -15.4% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 40.0x Fair | +7% vs avg | +22.5% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.5x Fair | +3% vs avg | +30.0% |
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.2x Undervalued | -17% vs avg | +22.8% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 27.6x Undervalued | -26% vs avg | +43.2% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 36.3x Fair | -3% vs avg | +9.4% |
ASTRAZENECA PHARMA IND LT trades at a premium (106.8x vs peer avg 37.5x), implying higher growth or quality expectations from the Pharmaceuticals cohort. Peers include AKUMS DRUGS AND PHARMA L, BLUE JET HEALTHCARE LTD, ABBOTT INDIA LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹683 CrJun 2026Latest net profit
₹38 CrJun 2026Latest EPS
₹15.17Jun 2026Net margin
7.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 295 | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 | 559 | 612 | 579 | 683 |
| Expenses + | 228 | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 | 567 | 518 | 634 |
| Operating Profit | 67 | 53 | 15 | 49 | 38 | 53 | 77 | 86 | 81 | 75 | 45 | 61 | 49 |
| OPM % | 23% | 17% | 4.9% | 13% | 10% | 13% | 17% | 18% | 15% | 13% | 7% | 11% | 7% |
| Other Income + | 8 | 25 | 10 | 9 | -49 | 8 | -26 | 10 | 11 | 1 | 7 | 5 | 9 |
| Interest | 0 | 0 | 1 | -0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 | 3 | 4 | 6 | 5 |
| Profit before tax | 71 | 73 | 20 | 54 | -15 | 51 | 42 | 78 | 75 | 73 | 47 | 58 | 51 |
| Tax % | 25% | 29% | 23% | 27% | -22% | 25% | 27% | 26% | 25% | 26% | 30% | 23% | 25% |
| Net Profit + | 54 | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 | 54 | 33 | 45 | 38 |
| EPS in Rs | 21.54 | 20.95 | 6.32 | 15.79 | -4.72 | 15.37 | 12.34 | 23.30 | 22.33 | 21.69 | 13.04 | 17.95 | 15.17 |
| Raw PDF | |||||||||||||
| YOY Sales Growth % | 27.18% | 31.74% | 22.41% | 34.60% | 31.15% | 31.16% | 43.98% | 25.39% | 35.81% | 37.03% | 38.90% | 20.42% | 29.73% |
| Material Cost % | 37% | 39% | 48% | 56% | 59% | 55% | 56% | 54% | 56% | 58% | 60% | 68% | 66% |
| Employee Cost % | 19% | 21% | 21% | 15% | 16% | 17% | 14% | 14% | 12% | 11% | 15% | 8% | 12% |
| Exceptional items | 0.00 | 16.43 | 0.00 | 0.00 | -57.56 | 0.00 | -33.55 | -5.68 | -0.36 | -5.29 | 1.48 | -1.08 | -0.24 |
| Other income normal | 8.10 | 8.37 | 9.66 | 8.66 | 8.35 | 8.15 | 7.98 | 16.15 | 11.24 | 6.17 | 5.13 | 5.95 | 9.23 |
| Exceptional items AT | 0.00 | 11.66 | 0.00 | 0.00 | -46.81 | 0.00 | -23.83 | -4.02 | -0.25 | -3.91 | 1.04 | -0.81 | -0.18 |
| Profit excl Excep | 53.86 | 40.71 | 15.80 | 39.48 | 35.02 | 38.43 | 54.68 | 62.27 | 56.08 | 58.13 | 31.55 | 45.69 | 38.11 |
| Profit for PE | 53.86 | 40.71 | 15.80 | 39.48 | 35.02 | 38.43 | 54.68 | 62.27 | 56.08 | 58.13 | 31.55 | 45.69 | 38.11 |
| Profit for EPS | 53.86 | 52.37 | 15.80 | 39.48 | -11.79 | 38.43 | 30.85 | 58.25 | 55.83 | 54.22 | 32.59 | 44.88 | 37.93 |
| YOY Profit Growth % | 167.30% | 25.03% | -46.08% | -19.63% | -34.98% | -5.60% | 246.08% | 57.73% | 60.14% | 51.26% | -42.30% | -26.63% | -32.04% |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Press Release / Media Release